<DOC>
	<DOCNO>NCT00132899</DOCNO>
	<brief_summary>The primary objective compare efficacy safety infliximab plus methotrexate infliximab alone long-term control sign symptoms Crohn 's disease ( CD ) patient symptoms persistent enough require corticosteroid therapy .</brief_summary>
	<brief_title>COMMIT ( Combination Of Maintenance Methotrexate-Infliximab Trial )</brief_title>
	<detailed_description>The current approach treatment Crohn 's Disease base `` step care '' . This strategy relatively ineffective long-term management patient require treatment corticosteroid . Although azathioprine , methotrexate infliximab modestly effective high-risk population , long-term corticosteroid-free response rate low . Thus combination therapy attractive option explore . Based favourable experience dual therapy treatment rheumatoid arthritis demonstrate efficacy methotrexate corticosteroid-dependent CD , expect combination therapy methotrexate infliximab significantly effective infliximab monotherapy . Furthermore combined therapy likely highly effective prevent formation antibody infliximab important limitation continue successful use drug . This randomized , placebo-controlled , double-blind , parallel group , multi-centre study . Subjects initiate corticosteroid induction therapy within precede 6 week randomize ( irrespective CDAI define disease activity ) 1:1 ratio either methotrexate placebo period 50 week combination infliximab administer 8 infusion . Randomization stratify : - Treatment without Imuran/6-mercaptopurine 2-12 month prior randomization ; - Prednisone dose &lt; 20 mg ≥20 mg daily randomization ; - CDAI &lt; 150 ≥150 randomization .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male , nonpregnant/nonlactating female , 18 old Established Crohn 's disease active symptom require prednisone therapy . Females childbearing potential must negative pregnancy test must agree use adequate contraception Intolerance hypersensitivity infliximab , methotrexate , prednisone know allergy murine protein chimeric protein Are pregnant , nursing , plan pregnancy ( men woman ) 6 month study In 2 month prior screen , serious infection , hospitalize and/or treat intravenous ( IV ) antibiotic infection . In 6 month prior screen , opportunistic infection . After screen , need continue nonstudy medical therapy CD In 8 week prior screen , receive following : systemic steroid therapy , azathioprine , 6mercaptopurine , cyclosporine , probiotic product , omega3 fatty acid Have receive following : biologics last 6 month ; methotrexate last year ; and/or ever receive infliximab . Have follow : biopsyproven cirrhosis , clinically important lung disease , preexist demyelinate disorder , systemic lupus erythematosus , congestive heart failure , diabetes mellitus ( insulin dependent ) , increase risk steroidrelated side effect , body weight 40 % high standard , human immunodeficiency virus and/or hepatitis B hepatitis C Have follow : active drain fistula primary manifestation CD ; document short bowel syndrome ; stoma ; severe , and/or fix symptomatic stenosis intestine . Have follow : clinically important bowel obstruction last 3 month ; bowel resection last 3 month ; and/or intraabdominal surgery within 6 month . Clinically significant impairment cardiac , liver renal function ; central nervous system ( CNS ) , pulmonary , hematological , immunological , vascular gastrointestinal disease addition CD ; current malignancy malignancy within 5 year prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>multi-centre randomize placebo-controlled</keyword>
	<keyword>infliximab</keyword>
	<keyword>methotrexate</keyword>
	<keyword>inflammatory bowel disease</keyword>
</DOC>